Revance Therapeutics (RVNC) Misses Q1 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.09 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Natural Foods (UNFI) Reports In-Line Q3 EPS ; Offers Outlook
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance